In 2022, the market for Biologics CDMO was estimated to be worth USD 11.27 billion. By 2027, it is anticipated to reach USD 21.90 billion, with a CAGR of 11.51% from 2022 to 2027. (Henceforth referred to as the forecast period). The demand for services from contract manufacturing and contract development manufacturing firms will increase as more businesses in the pharmaceutical industry contemplate logistics solutions.

·         The global economy, an ageing and expanding population, and the introduction of new products are all driving the exponential expansion of the pharmaceutical sector. Large molecules, including biologics, biosimilars, and cell and gene therapies, are anticipated to see the greatest increase throughout the projected period, even if small molecules still hold a significant market share.

·         Despite the fact that big molecules often have lesser quantities, the market is expanding more quickly. By 2023, the market for big molecules, which includes original biologics, biosimilars, and cell and gene treatments, is anticipated to reach USD 133 billion thanks to absolute increase. According to Results Healthcare, the market for originator biologics would be worth USD 371 billion by 2023.